drugset

drugset / Trial / NCT03736447

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447 ↗

Phase 3 Completed 146 enrolled Aimmune Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \< 4 years.

Timeline

Start: 2018-12-27
Primary completion: 2022-07-05
Completion: 2022-07-05

Publications

Du Toit G, Brown KR, Vereda A, Irani AM, Tilles S, Ratnayake A, Jones SM, Vickery BP. Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age. NEJM Evid. 2023 Nov;2(11):EVIDoa2300145. doi: 10.1056/EVIDoa2300145. Epub 2023 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	AR101	Protein / enzyme biologic	—	Oral

Indications